OTC · Materials
BIOLARGO, INC. (BLGO)
As-reported financials and recent SEC filings for BIOLARGO, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$7.8M
Net income
$-15.2M
Net margin
—
Diluted EPS
—
ROE
-995.3%
P/E (TTM)
—
Market cap
—
Debt / equity
1.4×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $7.8M | $17.8M | $12.2M | $5.9M | $2.5M |
| Gross profit | $3.4M | $7.9M | $6.2M | $2.9M | $1.1M |
| Operating income | $-14.9M | $-4.3M | $-4.6M | $-5.4M | $-6.8M |
| Net income | $-15.2M | $-4.3M | $-4.6M | $-5.1M | $-6.9M |
| Diluted EPS | — | — | — | — | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-06-24
View on EDGAR →10-Q2026-05-15
View on EDGAR →8-K2026-05-06
View on EDGAR →Largest Materials peers
Go deeper on BLGO
Search BIOLARGO, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.